Renal Pelvis Squamous Cell Carcinoma
There are 3 clinical trials for renal pelvis squamous cell carcinoma, of which 2 are open and 1 is completed or closed. Of the trials that contain renal pelvis squamous cell carcinoma as an inclusion criterion, 3 are phase 2 (2 open).
Durvalumab, ipilimumab, and nilotinib are the most common interventions in renal pelvis squamous cell carcinoma clinical trials.
Significant Genes in Renal Pelvis Squamous Cell Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for renal pelvis squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and renal pelvis squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.